Gary L. Rosner, ScD, on Bayesian Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

Oct

Today In Oncology

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Related Videos

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Varsha Gandhi, PhD, on Ibrutinib

PARP Rechallenge Slows Ovarian Cancer Progression in Platinum-Sensitive Disease

Preclinical Study Examines Relationship Between Aging Breast Tissue and Invasive Breast Cancer

Primary Tumor Resection Followed by Systemic Treatment vs Systemic Treatment in Metastatic Colorectal Cancer 60-Day Mortality

First-Line Fulvestrant/Palbociclib vs Letrozole/Palbociclib for Endocrine-Sensitive, HR-Positive, HER2-Negative Advanced Breast Cancer

Global Analysis of National Health System Characteristics and Breast Cancer Mortality and Stage at Diagnosis